Solventum (SOLV) Projected to Post Quarterly Earnings on Thursday

Solventum (NYSE:SOLV) is expected to be announcing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of $1.50 per share and revenue of $1.9613 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Solventum Stock Down 0.6%

Shares of NYSE SOLV opened at $72.52 on Tuesday. The company has a market capitalization of $12.58 billion, a P/E ratio of 8.35, a P/E/G ratio of 6.70 and a beta of 0.35. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The company has a 50 day simple moving average of $79.04 and a 200-day simple moving average of $76.19. Solventum has a 1 year low of $60.70 and a 1 year high of $88.20.

Solventum declared that its Board of Directors has authorized a stock repurchase program on Thursday, November 20th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to repurchase up to 7.5% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of research firms have commented on SOLV. KeyCorp upgraded Solventum from a “sector weight” rating to an “overweight” rating and set a $97.00 target price on the stock in a research report on Monday, January 26th. Zacks Research downgraded Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Piper Sandler reaffirmed an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th. Finally, Stifel Nicolaus boosted their price target on shares of Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Seven analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $90.83.

Institutional Investors Weigh In On Solventum

Large investors have recently added to or reduced their stakes in the business. CrossGen Wealth LLC purchased a new position in Solventum in the 4th quarter valued at approximately $25,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Solventum in the third quarter valued at $25,000. CYBER HORNET ETFs LLC purchased a new position in Solventum in the second quarter valued at $28,000. MUFG Securities EMEA plc purchased a new position in Solventum in the second quarter valued at $31,000. Finally, State of Wyoming acquired a new position in Solventum during the 2nd quarter worth $33,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.